Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.

BACKGROUND: Imipenem-relebactam is a new ß-lactam and ß-lactamase inhibitor combination to treat carbapenem-resistant gram-negative bacteria infections. However, difference in carbapenem resistant mechanisms existed with geographic variations. OBJECTIVE: To evaluate the susceptibility of imipenem-relebactam to 660 carbapenem-nonsusceptible Enterobacteriaceae isolates in Taiwan and to identify the in vivo efficacy with a Caenorhabditis elegans model. METHODS: 188 carbapenem-nonsusceptible Escherichia coli isolates and 472 carbapenem-nonsusceptible Klebsiella pneumoniae isolates were collected from a national surveillance study in Taiwan. The antimicrobial susceptibility profiles and carbapenemase distributions were determined. An agar dilution method was performed to evaluate the in vitro activities of imipenem monotherapy and imipenem-relebactam combination. Contributions of metallo-carbapenemase to imipenem-relebactam susceptibility was investigated via EDTA treatment. A C. elegans model was used to evaluate the in vivo efficacy of imipenem-relebactam combination. RESULTS: 87.8% and 82.2% susceptibility to imipenem-relebactam was observed for 188 carbapenem-nonsusceptible E. coli and 472 carbapenem-nonsusceptible K. pneumoniae, respectively. However, poor activities of imipenem-relebactam was observed against 23 metallo-carbapenemase producers tested in this study. In the in vivo C. elegans model, imipenem-relebactam significantly rescued nematodes from the infection of a blaKPC-producing K. pneumoniae isolate. CONCLUSION: Our study supports that imipenem-relebactam is a potential therapy against carbapenem-nonsusceptible Enterobacteriaceae, and to our knowledge, this is the first report of evaluation for imipenem-relebactam efficacy against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.

In Vitro and In Vivo Evaluations of ß-Lactam/ß-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan.

Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime-avibactam and aztreonam-avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must be considered for antibiotic susceptibility patterns varied. Thus, we sought to assess the susceptibilities of ceftazidime-avibactam and aztreonam-avibactam against 660 carbapenem-nonsusceptible Enterobacteriaceae isolates (472 Klebsiella pneumoniae and 188 Escherichia coli) collected during an earlier Taiwan surveillance study. Agar dilution method was used to determine ceftazidime-avibactam and aztreonam-avibactam susceptibility. Metallo-carbapenemase's contribution to resistance were investigated with EDTA addition. The in vivo efficacies were evaluated using a Caenorhabditis elegans model. High susceptibility rates were observed for ceftazidime-avibactam and aztreonam-avibactam against the 472 carbapenem-nonsusceptible K. pneumoniae (CnsKP) (85.2% and 95.3%, respectively) and 188 carbapenem-nonsusceptible E. coli (CnsEC) isolates (91.5% and 94.1%, respectively). For non-metallo-carbapenemase producers, the susceptibility rates for ceftazidime-avibactam were 93.6% for CnsKP and 97.7% for CnsEC, whereas only 7.1% CnsKP and 11.1% CnsEC in metallo-carbapenemase producers were susceptible to ceftazidime-avibactam. Of all isolates, 95.3% CnsKP and 94.1% CnsEC were susceptible to aztreonam-avibactam. In C. elegans model, ceftazidime-avibactam and aztreonam-avibactam revealed effective against a blaKPC-producing K. pneumoniae isolate in vivo. Our results propose a positive therapeutic approach for both combinations against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.

Contributions of insertion sequences conferring colistin resistance in Klebsiella pneumoniae.

BACKGROUND: Increasing colistin consumption is leading to expanding colistin resistance in Klebsiella pneumoniae worldwide, but particularly in Asia. Epidemiological studies indicate a link between specific insertion sequences (ISs) and colistin resistance; however, proof of a colistin-IS correlation is lacking. OBJECTIVES: Colistin-resistant mechanisms, and in vitro and in vivo efficacies of colistin against K. pneumoniae with ISs were investigated. METHODS: Colistin-resistant genes, including mcr-1 gene, were detected in 49 colistin- and carbapenem-resistant K. pneumoniae isolates. crrCAB genetic environments were analysed using whole-genome sequencing and polymerase chain reaction (PCR) mapping. Identified ISs were cloned into pRK415 vectors and investigated for potential contributions to colistin resistance. A Caenorhabditis elegans model was employed for in vivo analysis. RESULTS: mgrB gene alterations (32/49, 65.3%) were identified as the major colistin-resistant mechanism, followed by variations in crrB (57.1%), pmrB (32.7%), phoQ (20.9%), pmrA (16.3%) and phoP (8.2%) genes. Furthermore, 21 of the 49 tested isolates (42.9%) contained the IS elements, ISKpn26, ISEcp1, IS10R, IS903B or ISKpn14 in mgrB or in the surrounding region of crrCAB, indicating an association between these ISs and colistin resistance. The frequencies of colistin resistance significantly increased in colistin-susceptible K. pneumoniae laboratory strains, with plasmids carrying different ISs from clinical strains. In vivo analysis revealed that K. pneumoniae harboring ISKpn26 was associated with decreased lifespan during colistin treatment, leading to an increased risk for colistin treatment failure. CONCLUSIONS: These findings indicate a correlation between diverse ISs and colistin resistance in K. pneumoniae and confirm a role for ISs in colistin treatment.